Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. Alexander Wyatt

Alexander Wyatt

Associate Professor
Academic Appointment
Associate Professor
Research Focus
Cancers
Degrees / Designations

B.Sc., DPhil

Contact Info
blogs.ubc.ca/wyattlab/
awyatt@prostatecentre.com
ResearchWyatt

Biography

Dr. Alexander Wyatt is an associate professor in the Department of Urologic Sciences at the University of British Columbia. He is also cross-appointed at the Vancouver Prostate Centre and BC Cancer. Dr. Wyatt has a DPhil in genetics from the University of Oxford. 

Dr. Wyatt’s primary research goals are to identify associations between molecular alterations in metastatic genitourinary cancers and clinical outcomes, and to translate these findings into clinical biomarkers. He has developed novel laboratory and computational techniques to study plasma circulating tumour DNA (ctDNA). Through application of these methods to clinical trial cohorts, his team has demonstrated that ctDNA is highly representative of metastatic lesions, and that somatic alterations detected in ctDNA can help predict prostate cancer therapy resistance or response. Learn more about his research here.

Dr. Wyatt is the chair of correlative sciences for genitourinary cancer trials run through the Canadian Cancer Trial Group (CCTG). He also serves as a member of the investigational new drug program executive committee. Dr. Wyatt directs the ctDNA screening strategy and the molecular tumor board for the first multi-center phase 2 umbrella trial in metastatic castration-resistant prostate cancer (NCT03385655, NCT02905318).

News and Awards

People in profile: Sarah Ng

May 7, 2025

Discovery offers new insights to understand and treat prostate cancer

Mar 20, 2025

Top Graduating Doctoral Student Award and Rising Star Award 2024 Recipients

Jul 9, 2024

A roadmap for individualized malignant prostate cancer care

Jan 4, 2024

With just a tablespoon of blood, B.C. researchers aim to transform cancer treatment

Jul 20, 2022

Top Graduating Doctoral Student Award and Rising Star Award 2022 Recipients

Jun 28, 2022

Liquid biopsy biomarker could revolutionize bladder cancer diagnostics and treatment

Jan 8, 2021

People in profile: Jack Bacon

May 21, 2020

Top Graduating Doctoral Student Award and Rising Star Award 2019 Recipients

Jul 18, 2019

An innovative new study advances personalized medicine for prostate cancer patients

Nov 27, 2018

People in profile: Gillian Vandekerkhove

Aug 24, 2018

Top Graduating Doctoral Student Award and Rising Star Award 2018 Recipients

May 24, 2018

Identifying treatment-resistant prostate cancer faster

Feb 15, 2018

Prostate cancer DNA test uses small blood sample, predicts response to drug

May 4, 2016

RNA sequence could help doctors to tailor unique prostate cancer treatment programs

Aug 26, 2014

Publications

  • Journal of the National Cancer Institute -

    Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

    Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME
  • Cancer discovery -

    Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

    Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN
  • European urology -

    Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.

    Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, Herberts C, Ritch E, Beja K, Loktionova Y, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW
  • Annals of oncology : official journal of the European Society for Medical Oncology -

    Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.

    Annala M, Fu S, Bacon JVW, Sipola J, Iqbal N, Ferrario C, Ong M, Wadhwa D, Hotte SJ, Lo G, Tran B, Wood LA, Gingerich JR, North SA, Pezaro CJ, Ruether JD, Sridhar SS, Kallio HML, Khalaf DJ, Wong A, Beja K, Schönlau E, Taavitsainen S, Nykter M, Vandekerkhove G, Azad AA, Wyatt AW, Chi KN
  • Nature communications -

    Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.

    Vandekerkhove G, Lavoie JM, Annala M, Murtha AJ, Sundahl N, Walz S, Sano T, Taavitsainen S, Ritch E, Fazli L, Hurtado-Coll A, Wang G, Nykter M, Black PC, Todenhöfer T, Ost P, Gibb EA, Chi KN, Eigl BJ, Wyatt AW
Working in the lab

Are you a researcher?

Update or create your researcher profile on our online directory.

Update Profile    Create New Profile

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy